This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Diagnosis of type 1 diabetes

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

diagnosis of type 1 diabetes mellitus

If symptoms of hyperglycaemia are present:

  • diagnosis is confirmed by a single random blood glucose of 11.1mmol/L or above

In asymptomatic patients (people with type 1 diabetes usually present with symptoms and it is uncommon for this condition to be diagnosed by routine screening):

  • diagnosis requires two separate blood glucose results in the diabetes range
  • fasting blood glucose 7.0mmol/L or above on 2 occasions and/or 2 hour blood glucose 11.1mmol/L or above 2 hours after a 75g oral glucose tolerance test

HbA1c

  • should not be used as a diagnostic test for type 1 diabetes as the rapid onset of the condition makes the HbA1c unreliable

Pancreatic autoantibodies:

  • anti-glutamic acid decarboxylase (anti-GAD), insulin autoantibodies (IAA), islet cell antibodies (ICA) are present at the time of diagnosis in 60-70% of people but the antibody titre declines with time
    • it is important to measure these antibodies soon after the diagnosis of T1D is made (if there is a doubt) since the amount of antibody positive patients decrease to 10-40% after 10-12 years
  • positive result supports the diagnosis, but a negative result does not exclude T1D
  • sensitivity of the test can be increased by measuring two antibodies (1).

Urine C-peptide:creatinine ratio

  • C-peptide is a useful indicator of beta cell function
  • measured in a urine sample collected 2 hours after a meal containing carbohydrate

In adults:

  • diagnose type 1diabetes on clinical grounds in adults presenting with hyperglycaemia, bearing in mind that people with type 1 diabetes typically (but not always) have one or more of:
    • ketosis
    • rapid weight loss
    • age of onset below 50 years
    • BMI below 25kg/m2
    • personal and/or family history of autoimmune disease

  • do not discount a diagnosis of type 1 diabetes if an adult presents with a BMI of 25 kg/m2 or above or is aged 50 years or above

  • do not measure C-peptide and/or diabetes-specific autoantibody titres routinely to confirm type 1 diabetes

  • consider further investigation in adults that involves measurement of C-peptide and/or diabetes-specific autoantibody titres if:
    • type 1 diabetes is suspected but the clinical presentation includes some atypical features (for example, age 50 years or above, BMI of 25 kg/m2 or above, slow evolution of hyperglycaemia or long prodrome) or
    • type 1 diabetes has been diagnosed and treatment started but there is a clinical suspicion that the person may have a monogenic form of diabetes, and C-peptide and/or autoantibody testing may guide the use of genetic testing or
    • classification is uncertain, and confirming type 1 iabetes would have implications for availability of therapy (for example, continuous subcutaneous insulin infusion [CSII or 'insulin pump'] therapy).

Note:

  • when measuring C-peptide and/or diabetes-specific autoantibody titres, take into account that:
    • autoantibody tests have their lowest false negative rate at the time of diagnosis, and that the false negative rate rises thereafter
    • C-peptide has better discriminative value the longer the test is done after diagnosis
    • with autoantibody testing, carrying out tests for 2 different diabetes-specific autoantibodies, with at least 1 being positive, reduces the false negative rate (2).

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.